1-1 of 1
Keywords: Phase II, second-line therapy
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase II Study of Docetaxel and Gefitinib as Second-Line Therapy in Gemcitabine Pretreated Patients with Advanced Pancreatic Cancer

Subject Area:
Oncology
Joanna M. Brell, Khalid Matin, Terry Evans, Robert L. Volkin, Gauri J. Kiefer, James J. Schlesselman, Shelley Dranko, Linda Rath, Amy Schmotzer, Diana Lenzner, Ramesh K. Ramanathan
Journal: Oncology
Oncology (2009) 76 (4): 270–274.
https://doi.org/10.1159/000206141
Published Online: 04 March 2009
... months (90% CI 4.3–5.4 months) (fig. 1 ). Progression-free survival was 1.8 months (90% CI 1.5–3 months) (fig. 2 ). Table 4 Response rate for all treated patients (intent-to-treat analysis) Docetaxel Gefitinib Pancreatic cancer Phase II, second-line therapy More than 200,000...
View article titled, Phase II Study of Docetaxel and Gefitinib as Second-Line Therapy in Gemcitabine Pretreated Patients with Advanced Pancreatic Cancer
Open the PDF for Phase II Study of Docetaxel and Gefitinib as Second-Line Therapy in Gemcitabine Pretreated Patients with Advanced Pancreatic Cancer in another window